Spanish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

papilledema/edema

El enlace se guarda en el portapapeles.
Página 1 desde 27 resultados

Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
TECHNICAL FIELD This invention relates to a method of treating eye disease. Specifically, this invention relates to a method of removing pathological fluid accumulation in subretinal and intra-retinal spaces, by administering P2Y receptor agonists such as certain dinucleotides to a subject in need

Treatment and prevention of retinal edema with dopaminergic antagonists

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
BACKGROUND OF THE INVENTION 1. Field of the Invention: This invention relates to pharmacological treatment and prevention of retinal edema and more particularly to treatment and prevention of cystoid macular edema by administration of dopaminergic antagonists. 2. Description of the Prior

Treatment and prevention of retinal edema with dopaminergic antagonists

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
BACKGROUND OF THE INVENTION 1. Field of the Invention: This invention relates to pharmacological treatment and prevention of retinal edema and more particularly to treatment and prevenion of cystoid macular edema by administration of dopaminergic antagonists. 2. Description of the Prior Art: Retinal

Treatment and prevention of retinal edema with dopaminergic antagonists

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
BACKGROUND OF THE INVENTION 1. Field of the Invention: This invention relates to pharmacological treatment and prevention of retinal edema and more particularly to treatment and prevention of cystoid macular edema by administration of dopaminergic antagonists. 2. Description of the Prior

Treatment of retinal edema with brinzolamide

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
The present invention is directed to the use of brinzolamide to treat retinal edema. BACKGROUND OF THE INVENTION In 1977, Miller, et al., did studies with bullfrogs and found that the pigment epithelium actively secretes sodium and calcium into the retinal space and absorbs chlorine and perhaps

Use of interferon-.beta. or .gamma. to treat retinal edema

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
TECHNICAL FIELD The present invention relates to a novel remedy or preventive which is useful for retinal edema, and particularly for cystoid macular edema. BACKGROUND ART Vision is the most important of the senses, and diseases affecting visual function, such as reduced vision or blindness are

Diagnostic method and system for detecting early age macular degeneration, maculopathies and cystoid macular edema post cataract surgery

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
FIELD OF THE INVENTION This invention relates to a method and system for using a calibrated retinoscope and parallel light technique to estimate the reflection of melanin particles in the retina to detect macular degeneration prior to physical symptoms. BACKGROUND OF THE INVENTION In the Western
FIELD OF THE INVENTION This invention relates to a method and system for using a calibrated retinoscope and parallel light technique to estimate the reflection of melanin particles in the retina to detect macular degeneration prior to physical symptoms. BACKGROUND OF THE INVENTION In the Western

Prevention and treatment for retinal ischemia and edema

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
BACKGROUND OF THE INVENTION Diabetes effects over 16 million Americans. The World Health Organization indicates that diabetes afflicts 120 million people worldwide, and estimates that this number will increase to 300 million by the year 2025. Diabetics are faced with numerous complications including

Prevention and treatment of retinal ischemia and edema

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
BACKGROUND OF THE INVENTION Diabetes affects over 16 million Americans. The World Health Organization indicates that diabetes afflicts 120 million people worldwide, and estimates that this number will increase to 300 million by the year 2025. Diabetics are faced with numerous complications including

RNAi-mediated inhibition of H1F1A for treatment of ocular angiogenesis

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
FIELD OF THE INVENTION The present invention relates to the field of interfering RNA compositions for inhibition of expression of hypoxia-inducible factor-1.alpha. (HIF-1.alpha.), the protein encoded by HIF1A mRNA, in ocular angiogenesis, including those cellular changes resulting from the

Method of treating edematous retinal disorders

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
TECHNICAL FIELD This invention relates to a method of treating edematous retinal disorders. Specifically, this invention relates to a method of removing pathological fluid accumulation in subretinal and intra-retinal spaces. BACKGROUND OF THE INVENTION The retinal pigment epithelium (RPE) lies in

P.sup.1-(2'-deoxycytidine 5'-)P.sup.4-(uridine 5'-)tetraphosphate, tetra-(alkali metal) salt, for treating cystic fibrosis

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
TECHNICAL FIELD This invention relates to a method of treating edematous retinal disorders. Specifically, this invention relates to a method of removing pathological fluid accumulation in subretinal and intra-retinal spaces. This invention also relates to dinucleoside polyphosphate salts, such as a

Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
TECHNICAL FIELD This invention relates to a method of treating edematous retinal disorders. Specifically, this invention relates to a method of removing pathological fluid accumulation in subretinal and intra-retinal spaces. This invention also relates to dinucleoside polyphosphate salts, such as a

Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
TECHNICAL FIELD This invention relates to a method of treating edematous retinal disorders. Specifically, this invention relates to a method of removing pathological fluid accumulation in subretinal and intra-retinal spaces. BACKGROUND OF THE INVENTION The retinal pigment epithelium (RPE) lies in
Únete a nuestra
página de facebook

La base de datos de hierbas medicinales más completa respaldada por la ciencia

  • Funciona en 55 idiomas
  • Curas a base de hierbas respaldadas por la ciencia
  • Reconocimiento de hierbas por imagen
  • Mapa GPS interactivo: etiquete hierbas en la ubicación (próximamente)
  • Leer publicaciones científicas relacionadas con su búsqueda
  • Buscar hierbas medicinales por sus efectos.
  • Organice sus intereses y manténgase al día con las noticias de investigación, ensayos clínicos y patentes.

Escriba un síntoma o una enfermedad y lea acerca de las hierbas que podrían ayudar, escriba una hierba y vea las enfermedades y los síntomas contra los que se usa.
* Toda la información se basa en investigaciones científicas publicadas.

Google Play badgeApp Store badge